Navigation

© Zeal News Africa

Kalorama Forecasts $2.3 Billion HbA1c Market by 2029, Driven by POC Growth, Emerging Markets, and Digital Innovation

Published 1 month ago3 minute read

, /PRNewswire/ -- Kalorama Information, a leading publisher of healthcare market research, has released The World Market for HbA1c Testing: Trends, Technologies, and Growth Opportunities, 2025, in conjunction with a related webinar held in April. This comprehensive report delivers critical insights for diagnostic developers, healthcare providers, investors, and strategic planners navigating the rapidly expanding global HbA1c testing market.

For over 20 years, Kalorama Information has been a trusted source of healthcare market research, specializing exclusively in areas such as in vitro diagnostics (IVD), medical devices, sequencing, cell and gene therapy, and pharmaceuticals. Kalorama Information remains a global leader in healthcare market intelligence, known for high-quality research, innovative analysis, and trusted insights used by top industry decision-makers and media outlets alike.

For over 20 years, Kalorama Information has been a trusted source of healthcare market research, specializing exclusively in areas such as in vitro diagnostics (IVD), medical devices, sequencing, cell and gene therapy, and pharmaceuticals. Kalorama Information remains a global leader in healthcare market intelligence, known for high-quality research, innovative analysis, and trusted insights used by top industry decision-makers and media outlets alike.

In 2024, the global HbA1c in vitro diagnostics (IVD) market generated $1.7 billion and is projected to reach $2.3 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.7%. The report underscores the growing role of HbA1c testing in diabetes screening, monitoring, and personalized care—particularly as point-of-care (POC) adoption accelerates to meet demand for fast, decentralized diagnostics.

"Laboratory-based testing has long been the gold standard for HbA1c," said Daniel Granderson, Senior Editor at Kalorama Information. "But with advancing technology and rising demand, we're seeing a significant shift toward POC testing. These platforms have been a major driver of diagnostics market growth over the past decade."

Key Findings:

Why This Report Matters Now:

As global diabetes rates climb and healthcare systems emphasize chronic disease management and cost control, HbA1c testing is central to improving outcomes. The integration of digital tools, biosensor innovation, and government screening programs is reshaping how and where testing is done. This report gives stakeholders a clear view of:

Who Should Read This Report:

Whether you're building a product roadmap, evaluating acquisition targets, or justifying a strategic pivot, this report provides the data, competitive intelligence, and trend forecasting you need to move forward with confidence.

Access the Report & Webinar

For more information or to request a custom consultation, contact:
Sheri Davie
Kalorama Information Sales Team
[email protected]

For all other inquiries contact:
Alisa Alvich
Marketing Director
[email protected] 

About Kalorama Information

For over 20 years, Kalorama Information has been a trusted source of healthcare market research, specializing exclusively in areas such as in vitro diagnostics (IVD), medical devices, sequencing, cell and gene therapy, and pharmaceuticals. Kalorama Information remains a global leader in healthcare market intelligence, known for high-quality research, innovative analysis, and trusted insights used by top industry decision-makers and media outlets alike.

SOURCE Kalorama Information

icon3

440k+
Newsrooms &
Influencers

icon1

9k+
Digital Media
Outlets

icon2

270k+
Journalists
Opted In

Origin:
publisher logo
Cision PR Newswire
Loading...
Loading...
Loading...

You may also like...